Biodel Trades Down Close To Net Asset Value (BIOD)
If you just read headlines on Biodel Inc. (Nasdaq: BIOD) this morning, you would have thought the news coming out of the company was either good or just neutral. Today was the exact opposite,…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 350More Blight For Merck (MRK)
Merck (MRK) and Schering-Plough (SGP) make two of the most widely sold drugs in the world. One is cholesterol drug Zetia. Another is a related drug called Vytorin. The sales of the treatments topped…
Another Stent Failure For Boston Scientific (BSX)
Investors have another reason to bail out of Boston Scientific (BSX). It has been in a battle with the medical research community for over a year fighting the perception that its drug-coated stents may…
Eli Lilly’s (LLY) Gift To The Funeral Industry
The National Funeral Directors Association must be sending “thank you” cards to Eli Lilly (LLY) and it partner Amylin (AMLN). Together, the companies developed and market diabetes drug Byetta. The firms had told the…
Biodel & Backers Tapping Cash Via Equity Sale (BIOD)
Biodel Inc. (NASDAQ: BIOD) has filed with the SEC to sell up to 8.5 million shares of common stock. The company will sell 5.5 million of the shares and 3 million of the shares…
Alpharma Already Wants More From King (ALO, KG)
Alpharma, Inc. (NYSE: ALO) has already responded to King Pharmaceuticals Inc. (NYSE: KG) regarding the $33.00 per share offer made by King to acquire Alpharma. As we noted based upon the premium trading to…
Eil Lilly (LLY) Death Drug Needs More Regulation
If there wasn’t enough already wrong with the FDA drug approval process, diabetes drug Byetta, created for patients by Elli Lilly (LLY) and Amylin Pharmaceuticals (AMLN) is killing more people. The news follows an…
24/7 Wall St. Biotech Report: Short-Selling And Splits (AMGN)(CELG)
Short sellers moved out of biotech stocks in the latest period according to Biohealth Investor. The short interest in Amgen (AMGN) dropped 22% and Calgene (CELG) fell 20%.
Illumina Gets Secondary Behind It (ILMN)
Illumina Inc. (NASDAQ: ILMN) has priced its proposed secondary offering of 3.5 million shares at $87.50 per share. This will result in net proceeds of roughly $297.9 million. The sole manager of the offering…
Alnylam Cancels Conference… What’s Brewing? (ALNY)
We just saw a report out of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) that may get traders moving on both sides of the stock. The company has just announced that management will not be presenting…
Icahn & ImClone Merger Game with Bristol-Myers: Bluff vs. Chicken (IMCL, BMY)
Carl Icahn and friends at ImClone Systems Incorporated (NASDAQ: IMCL) have now formally responded to Bristol-Myers Squibb Company (NYSE: BMY) regarding the cash buyout of the company. The company’s board of directors has formed…
CardioNet Defies Prior Secondary Trends (BEAT)
CardioNet, Inc. (NASDAQ: BEAT) is holding up rather well considering the discount pricing of a secondary offering. The company sold 5 million shares at a price of $26.50 per share. All shares were being…
Why Biogen & Elan TYSABRI News Should Have Been Expected (BIIB, ELN)
This morning’s share price reaction seen in Biogen-Idec Inc. (NASDAQ: BIIB) and Elan Corp. plc (NYSE: ELN) is severe. We do not want to try to sound as though this TYSABRI news is something…
Icahn, ImClone, Bristol-Myers… A 3-Way Marriage (IMCL, BMY)
Another biotech giant is biting the dust via a buyout offer. ImClone Systems Inc. (NASDAQ: IMCL) has been given a buyout offer from Bristol-Myers (NYSE: BMY) at $60.00 per share. As per the filing:…
Align’s Guidance: Wearing a Retainer in Public (ALGN)
Align Technology Inc. (NASDAQ: ALGN) has just posted some mixed earnings. Regardless of Wall Street’s and Main Street’s love of Invisalign, the stock is being pounded. The company reported earnings at $0.06 EPS on…